Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.

Raffaele Palmieri,Sarah A. Buckley,Megan Othus,Anna B. Halpern,Mary-Elizabeth M. Percival,Bart L. Scott,Paul C. Hendrie,Pamela S. Becker,Vivian G. Oehler,Elihu H. Estey,Roland B. Walter

Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.

2020

Raffaele Palmieri
Sarah A. Buckley
Megan Othus
Anna B. Halpern
Mary-Elizabeth M. Percival
Bart L. Scott
Paul C. Hendrie
Pamela S. Becker
Vivian G. Oehler
Elihu H. Estey
Roland B. Walter

Despite the introduction of molecularly targeted therapeutics, multi-agent chemotherapy remains important for the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) [1...

Keywords:

Cladribine/Cytarabine
Refractory
Oncology
Immunology
Mitoxantrone
Decitabine
Medicine
Internal medicine
Myeloid leukemia
Diabetes mellitus
Myeloid Neoplasm
relapsed refractory
newly diagnosed

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations